Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$256.24 – $474.99
63% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
PFD
P/S (TTM)
17.1
EV / FCF (TTM)
656
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
www.bruker.comNo one on the platform currently holds BRKRP.
| Institution | Shares | Reported |
|---|---|---|
| Scion Asset Managementas of 2025-09-30 | 48,334 | $13.1M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-14 | $3.9844 | 2026-09-01 |
| 2026-05-15 | $3.9844 | 2026-06-01 |
| 2026-02-13 | $3.9844 | 2026-03-02 |
| 2025-11-14 | $3.6745 | 2025-12-01 |
No one on the platform has traded BRKRP yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -2.3% | 11.1% | 14.1% | — | — | — |
| Rev. Growth % | 2.1% | 11.6% | ||||
| Profit Margin % | -0.3% | 8.1% | 8.2% | |||
| Free Cash Flow Margin % | 0.4% | 5.3% | 6.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +5.3% on the P/E track.
At today's price, your expected annual return is +10.3% on the P/E track.
At today's price, your expected annual return is +14.6% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.6B | +3.9% | $2.12 | $2.10–$2.15 | 185.1× | 1 |
| 2027 | $3.7B | +4.1% | $2.40 | $2.37–$2.43 | 164.1× | 1 |
| 2028 | $3.9B | +5.7% | $2.79 | $2.75–$2.83 | 141.1× | 1 |
| 2029 | $4.2B | +8.1% | $3.27 | $3.23–$3.31 | 120.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.38 | $0.49 | +27.3% |
| 2026-05-06 | $0.23 | $0.31 | +35.1% |
| 2026-02-12 | $0.65 | $0.59 | -9.2% |
| 2025-11-03 | $0.35 | $0.45 | +27.2% |
| 2025-08-04 | $0.41 | $0.32 | -22.2% |
| 2025-05-07 | $0.44 | $0.47 | +7.9% |
| 2025-02-13 | $0.74 | $0.76 | +3.1% |
| 2024-11-05 | $0.60 |
| $0.60 |
| -0.2% |
| $55.0B |
| — |
| EWEdwards Lifesciences Corporation | $85.52 | +1.36% | $49.2B | — |
| HLNHaleon plc | $9.39 | +2.18% | $41.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.